Research analysts who have asked questions during MediWound earnings calls.
JJ
Joshua Jennings
TD Cowen
5 questions for MDWD
Also covers: ABT, ALUR, ATEC +20 more
Michael Okunewitch
Maxim Group
5 questions for MDWD
Also covers: BLFS, BLTE, BNGO +11 more
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for MDWD
Also covers: ABSI, BSEM, CGEN +24 more
Chase Knickerbocker
Craig-Hallum Capital Group
2 questions for MDWD
Also covers: AVDL, BFLY, BVS +17 more
Jeff Jones
Oppenheimer & Co. Inc.
2 questions for MDWD
Also covers: ABEO, CLRB, CMMB +8 more
CN
Chase Nicheboker
Craig-Hallum Capital Group
1 question for MDWD
FB
François Brisebois
Oppenheimer & Co. Inc.
1 question for MDWD
Also covers: ACHV, AQST, AVDL +11 more
ME
Maya Eskandarani
H.C. Wainwright & Co.
1 question for MDWD
MO
Michael Okudovich
Maxim Group
1 question for MDWD
R
RK
HC Wainright
1 question for MDWD
Also covers: CLGN, HOOK
Recent press releases and 8-K filings for MDWD.
MediWound Provides Corporate Update and Financial Outlook
MDWD
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- MediWound reported $17 million in revenue for the full year 2025 and maintained a cash, cash equivalents, and deposits position of $54 million as of December 31, 2025, with no debt.
- The company issued updated revenue guidance, projecting $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028.
- For EscharEx®, interim assessment and enrollment completion for the VALUE Phase III trial are expected by year-end 2026, with plans to initiate a Phase II study in diabetic foot ulcers (DFUs) in the second half of 2026 and an investigator-initiated trial (IIT) in pressure ulcers (PUs) in mid-2026.
- The expanded NexoBrid® manufacturing facility is now fully operational, increasing production capacity sixfold, with regulatory approvals targeted for 2026.
Jan 12, 2026, 12:08 PM
MediWound Provides Corporate Update and Financial Outlook
MDWD
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- MediWound reported $17 million in revenue for the full year 2025 and held a $54 million cash position with no debt as of December 31, 2025.
- The company issued updated revenue guidance, projecting $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028.
- Key operational milestones include the fully operational expanded NexoBrid® manufacturing facility targeting regulatory approvals in 2026, and expected interim assessment and enrollment completion by year-end 2026 for the EscharEx® VALUE Phase III trial, with expansion to additional chronic wound indications planned for 2026.
Jan 12, 2026, 12:00 PM
MediWound Reports Q3 2025 Financial Results and Strategic Progress
MDWD
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- MediWound reported Q3 2025 revenue of $5.4 million, a 23% increase year-over-year, and a net loss of $2.7 million, or $0.24 per share.
- The company strengthened its balance sheet with $60 million in cash as of September 30, 2025, following a $30 million equity financing and $3.5 million from warrant exercises.
- Enrollment for the EscharEx VALUE phase III trial for venous leg ulcers is progressing, and an updated market assessment estimates annual peak sales of approximately $831 million for EscharEx in the US.
- NexoBrid's expanded manufacturing facility commissioning is complete, increasing production capacity six-fold, with full operational capacity expected by year-end 2025. US partner Vericel reported record quarterly revenue for NexoBrid, up 38% year-over-year.
Nov 20, 2025, 1:30 PM
MediWound Reports Q3 2025 Financial Results and Strategic Progress
MDWD
Earnings
New Projects/Investments
Guidance Update
- For the third quarter of 2025, MediWound reported revenue of $5.4 million, marking a 23% increase year-over-year compared to Q3 2024, and a net loss of $2.7 million, or $0.24 per share. The company's cash, cash equivalents, and short-term deposits totaled $60 million as of September 30, 2025.
- MediWound continues to advance its EscharEx VLU phase III trial, targeting 216 patients across approximately 40 sites. An updated US market assessment estimates annual peak sales for EscharEx at about $831 million, driven by robust clinical data and health economic benefits.
- The company completed the commissioning of its expanded NexoBrid manufacturing facility, which has six times greater production capacity and is expected to reach full operational capacity by year-end 2025. Vericel, MediWound's US partner, reported record quarterly revenue for NexoBrid, with a 38% year-over-year and 26% sequential increase.
- MediWound strengthened its balance sheet with a $30 million equity financing from healthcare investors.
Nov 20, 2025, 1:30 PM
MDWD Reports Q3 2025 Financial Results and Provides Business Updates
MDWD
Earnings
Guidance Update
New Projects/Investments
- MediWound reported Q3 2025 revenue of $5.4 million, a 23% increase year-over-year, and a net loss of $2.7 million or $0.24 per share, an improvement from the prior year's net loss. The company ended Q3 2025 with $60 million in cash, cash equivalents, and short-term deposits.
- The expanded NexoBrid manufacturing facility has been commissioned, increasing production capacity six times, with full operational capacity anticipated by year-end 2025. NexoBrid's U.S. partner, Vericel, reported record quarterly revenue, up 38% year-over-year.
- Progress continues for EscharEx, with ongoing enrollment in the VALUE Phase III trial for venous leg ulcers (VLU) and positive FDA feedback for the diabetic foot ulcer (DFU) program, targeting study initiation in H2 2026.
- An updated U.S. market assessment for EscharEx projects annual peak sales of approximately $831 million, an increase from previous estimates, driven by potential higher pricing due to health economic benefits.
Nov 20, 2025, 1:30 PM
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MDWD
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- MediWound Ltd. reported revenue of $5.4 million for the third quarter of 2025, representing a 23% increase year-over-year. The company's net loss for the quarter was $2.7 million, or $0.24 per share.
- As of September 30, 2025, MediWound had $60 million in cash, cash equivalents, and short-term deposits, with its balance sheet strengthened by a $30 million equity financing.
- Enrollment is ongoing in the VALUE Phase III study of EscharEx for venous leg ulcers, and an independent assessment estimated a peak sales opportunity of approximately $831 million for EscharEx.
- The commissioning of the expanded NexoBrid manufacturing facility has been completed, with full operational capacity expected by year-end 2025, which will increase production capacity sixfold.
Nov 20, 2025, 12:04 PM
Vericel Reports Strong Third Quarter 2025 Financial Results and Reaffirms Full-Year Guidance
MDWD
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Vericel Corporation reported record third quarter 2025 total revenue of $67.5 million, with MACI revenue growing 25% to $55.7 million, and achieved a net income of $5.1 million for the quarter ended September 30, 2025.
- The company's non-GAAP adjusted EBITDA for Q3 2025 increased 69% to $17.0 million, representing 25% of revenue, and generated $22.1 million in operating cash flow.
- Vericel reaffirmed its full-year 2025 total revenue guidance of $272 to $276 million and expects MACI full-year revenue growth in the low 20% range.
- As of September 30, 2025, Vericel held $185 million in cash and investments and had no debt.
Nov 6, 2025, 12:55 PM
MediWound Completes Commissioning of Expanded NexoBrid Manufacturing Facility
MDWD
New Projects/Investments
- MediWound Ltd. has successfully completed the commissioning of its expanded GMP manufacturing facility in Yavne, Israel, dedicated to NexoBrid® production.
- This milestone represents a significant step towards achieving full operational readiness by year-end 2025.
- The expanded facility is expected to increase NexoBrid® production capacity by approximately sixfold.
- This capacity expansion aims to ensure a reliable and scalable global supply of NexoBrid® to meet rising demand across more than 40 approved markets.
Nov 3, 2025, 1:00 PM
MediWound Ltd. Completes $30 Million Ordinary Share Offering
MDWD
New Projects/Investments
- MediWound Ltd. entered into a securities purchase agreement on September 29, 2025, and closed an offering on September 30, 2025, for 1,734,105 ordinary shares at a purchase price of $17.30 per share.
- The offering generated approximately $30.0 million in gross proceeds.
- The company intends to use the net proceeds primarily to support EscharEx®'s pre-commercial activities, enhance its large-scale manufacturing capabilities, and for general corporate purposes.
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a cash transaction fee equal to 7.0% of the aggregate gross proceeds (with variations for certain designated investors), a non-accountable expense allowance of $85,000.00, and clearing fees of $15,950.00.
Sep 30, 2025, 8:38 PM
MediWound Announces $30 Million Registered Direct Offering
MDWD
New Projects/Investments
- MediWound Ltd. announced a $30 million registered direct offering of 1,734,105 ordinary shares at a purchase price of $17.30 per share.
- The offering, led by a U.S.-based prominent mutual fund and other healthcare-focused investors, is expected to close on or about September 30, 2025.
- The net proceeds from the offering will primarily be used to support EscharEx's pre-commercial activities, enhance large-scale manufacturing capabilities, and for general corporate purposes.
Sep 29, 2025, 12:49 PM
Quarterly earnings call transcripts for MediWound.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more